about
Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatinGenetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencingDynamics of hepatitis B virus quasispecies in association with nucleos(t)ide analogue treatment determined by ultra-deep sequencingEvolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing.Pretransplant serum hepatitis C virus RNA levels predict response to antiviral treatment after living donor liver transplantationEstablishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b.Spontaneous clearance of hepatitis C virus after liver transplantation: a report of four cases.Helicobacter pylori in solid-organ transplant recipient.Dynamics of defective hepatitis C virus clones in reinfected liver grafts in liver transplant recipients: ultradeep sequencing analysis.Chronic rejection associated with antiviral therapy for recurrent hepatitis C after living-donor liver transplantation.Transcriptional activities of p73 splicing variants are regulated by inter-variant association.Interferon-Free Therapy for Hepatitis C in Liver Transplant Recipients.Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation; a Japanese multicenter experience.Complete inactivation of DNMT1 leads to mitotic catastrophe in human cancer cells.Expression of activation-induced cytidine deaminase in human hepatocytes during hepatocarcinogenesis.Impact of Donor Age on Recipient Survival in Adult-to-adult Living-donor Liver Transplantation.Expression of APOBEC2 is transcriptionally regulated by NF-kappaB in human hepatocytes.Anti-viral protein APOBEC3G is induced by interferon-alpha stimulation in human hepatocytes.Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.Simultaneous occurrence of inflammatory bowel disease and myelodysplastic syndrome due to chromosomal abnormalities in bone marrow cells.Inactivation of Dnmt3b in mouse embryonic fibroblasts results in DNA hypomethylation, chromosomal instability, and spontaneous immortalization.Sonazoid-enhanced ultrasonography guidance improves the quality of pathological diagnosis in the biopsy of focal hepatic lesions.Wnt/beta-catenin signaling suppresses apoptosis in low serum medium and induces morphologic change in rodent fibroblasts.Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after living-donor liver transplantation: A Japanese multicenter experience.[Treatment for hepatitis C before and after liver transplantation].Slow Progression of Poorly Differentiated Gastric Carcinoma Associated with Epstein-Barr Virus Infection: 12-year Follow-up.Long-term efficacy of hepatitis B vaccination as post-transplant prophylaxis in hepatitis B surface antigen (HBsAg) positive recipients and HBsAg negative recipients of anti-hepatitis B core positive grafts.Safe and effective treatment with daclatasvir and asunaprevir in a liver transplant recipient with severe cholestatic hepatitis C.A functioning black adenoma of the adrenal gland.Islet-cell hyperplasia causing hyperinsulinemic hypoglycemia in an adult.Reactivation from occult HBV carrier status is characterized by low genetic heterogeneity with the wild-type or G1896A variant prevalence.Successful telaprevir treatment in combination of cyclosporine against recurrence of hepatitis C in the Japanese liver transplant patients.Overproduced p73alpha activates a minimal promoter through a mechanism independent of its transcriptional activity.Effects of double-filtration plasmapheresis combined with interferon plus ribavirin for recurrent hepatitis C after living donor liver transplantation.Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation.Effect of maintenance therapy with low-dose peginterferon for recurrent hepatitis C after living donor liver transplantation.Efficacy and safety of prophylaxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis B recurrence after living-donor liver transplantation.De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation.Limited benefit of biochemical response to combination therapy for patients with recurrent hepatitis C after living-donor liver transplantation.Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study.
P50
Q28187783-70655066-4978-4967-80DB-122226DAE802Q28477175-344DB3B2-396B-44F0-9BC2-1DDB267C168BQ28482355-58D1AE74-B401-4E93-9243-FD9D459247BBQ30843427-CA437D09-CB52-49AD-8EE6-DFC28505EC88Q34625761-5FE90592-1747-4100-AAED-F3ED66D26DDBQ35169651-332F12C3-2653-4668-9C5A-70D3D2374F70Q36403347-71D910CD-C68C-4DE6-9FDF-D25B540A0704Q37342562-6434C1CD-3BD4-4038-BBCF-D1434C617E35Q37470369-7A0545BF-7E40-4EC5-97F4-B51AA328036FQ38155323-F1ED8735-A3DC-4F09-BB10-ACA250FF797BQ38300240-C40B9E61-8CF7-40B2-A049-124257275290Q38579934-6638EE79-D42D-4F32-952F-E170BC3CDABFQ40053650-1AC231A7-0EF0-465A-A857-354EAFF00529Q40166601-B802614B-B3E7-4CA2-BB82-FE6ECCDDE971Q40215373-A894AE03-3402-42CB-8706-C2ED5CF63A66Q40294964-3B4A8D96-21A2-4408-91F9-E87219F2BEABQ40326775-809E4CEC-0C33-454E-98AC-E3C3686ED7D8Q40326926-43D0C046-BAFB-4DD4-8782-F53FAFC219EDQ40352380-8828F9B1-45A8-4C4A-A403-919845FD3937Q40391604-609E9EE8-6E5A-42F3-B88B-0432600DE742Q40448471-425F2721-376D-4EB2-8C01-23160AEFECCEQ40500074-5696125A-DDC2-4EA1-97A0-8987AF9497E8Q40718642-86F26759-4906-4873-9B9D-EFBFF9BA1BCFQ40896916-F0C9A693-D0CB-4665-8CFB-7172947DC550Q40930024-D0EF7747-3101-4A0B-A584-5495C105A66CQ41161925-C675D2D4-7BF1-4854-A01D-80C24FE4E480Q41390929-596A42BC-A42B-43D4-9553-89C0B062DE9FQ41470523-3D6467A3-6355-4769-9C6D-F664DFD244FCQ41523198-64170B6C-0D84-4CA0-B39D-EF32083FE61BQ41719079-6587944A-E6E2-4807-8A26-226152B79E0EQ42220386-DF709F36-5431-4665-8EF6-30D3CBBF00D2Q42247175-33BB831F-CF44-42B2-9AA4-B449B8A9E947Q42513771-A1223B60-63A8-42D7-A441-BB1104A86077Q42979457-CFE87149-1898-4338-90B6-A308D15812D7Q42994392-EB233B8A-16F7-4463-ADD1-C2DFD7F06F99Q43031601-29508EF5-54AA-4AA5-B048-67773B819003Q43585737-FB44E0F3-0F0C-4E1A-85D5-B74182CA5F85Q44033724-03257F3C-11A1-49BC-831B-DB14C1C75A3CQ44406753-F9F66560-213A-49A5-9151-2A7A8D242CDFQ45361548-8E45321A-BB74-4F29-B6D2-DF60BE72455B
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Yoshihide Ueda
@ast
Yoshihide Ueda
@en
Yoshihide Ueda
@es
Yoshihide Ueda
@nl
Yoshihide Ueda
@sl
type
label
Yoshihide Ueda
@ast
Yoshihide Ueda
@en
Yoshihide Ueda
@es
Yoshihide Ueda
@nl
Yoshihide Ueda
@sl
prefLabel
Yoshihide Ueda
@ast
Yoshihide Ueda
@en
Yoshihide Ueda
@es
Yoshihide Ueda
@nl
Yoshihide Ueda
@sl
P1053
S-7620-2016
P106
P21
P31
P3829
P496
0000-0003-3196-3494
P569
2000-01-01T00:00:00Z